Oaktree Specialty Lending Corporation (OCSL) Earnings Call Transcript
November 18, 2025
Earnings Call Speaker Segments
Thanks, Operator. This morning we put out our results for the 4th quarter and the full year 2025, together with the slide deck that goes with them, and you can find both in the Investor area of our site, oaktreespecialtylending.com. Prior to getting started, I'd like to note that what we say on this call contains forward-looking statements, which reflect where views currently stand regarding future operating results and financial performance, among other matters. What actually happens may differ materially from what those forward-looking statements imply or express. For a fuller discussion of these factors, please look at the applicable SEC filings. Oaktree has no obligation to update or revise any forward-looking statements. Let me also note that nothing said on this call is an offer to sell or a solicitation of an offer to buy any interest in an Oaktree fund. Investors and others ought to know that OCSL announces material information through the Investor area of its corporate website. The company urges investors, the media, and others to look at the information it posts on its website. With that, I'll hand things over to Matt Pendo, OCSL's President. Matt.
Thanks, Clark, and I appreciate everyone being on the call with us today. To kick things off, I'll give you a rundown of how we performed in the fiscal year and the fourth quarter. After that, Armen Panossian, who serves as our CEO and co-CIO, will offer his thoughts on what's happening in the market right now. Raghav Khanna, one of our co-CIOs, will walk you through the portfolio and what we've been investing in. Then Chris McKown, our CFO and Treasurer, will go over the financials, and after that we'll take your questions. For OCSL, the fourth quarter and the back half of fiscal 2025 showed consistent gains, even with a macro backdrop that stayed uneven. As we'll get into more deeply, the team put in serious effort to fix up positions that weren't producing income, uncover appealing places to invest, and bring down what we pay for capital. During the fourth quarter, adjusted net investment income came in at $0.40 per share, which is better than the $0.37 we posted the quarter before. That quarter-over-quarter gain comes from prepayment fees getting back to a more typical level, more dividend income, and reduced interest costs thanks to refinancings we did earlier in the year plus lower base rates. On top of that, we're still making headway on bringing down non-accruals, which is one of our main strategic priorities. When the year closed, non-accruals made up 2.8% of the portfolio at fair value, which is 20 basis points lower than the third quarter and 100 basis points below where we were a year ago. The board gave the green light last week to a dividend of $0.40 per share for the quarter, which lines up with both our dividend policy and what we earned in the 4th quarter. Although the rate cut the Federal Reserve made in September had no impact on 4th quarter earnings, net investment income will feel the effect of lower base rates during the December quarter. Like we've mentioned previously, there are multiple levers available to us at the corporate level and the JV level that can help counterbalance lower base rates and prop up net investment income. First off, we have room to carefully add leverage to the balance sheet, which boosts earning capacity and lets us put capital to work in attractive investments. With leverage at 0.97 times, our balance sheet is conservative and gives us plenty of financial flexibility. Second, we can keep refining our JVs. And lastly, bringing down non-accruals in equity positions will strengthen our ability to generate earnings. We can see a path toward: one, returning a chunk of our loans that previously weren't accruing to accrual status; two, monetizing some of those non-accruals; and three, monetizing equity positions. Whatever proceeds come from realizing non-accruals and equity will get redeployed into assets that produce income. Going forward, we'll keep assessing these levers and how much they might add to earnings and our dividend. With that, I'll hand things over to Armen for the latest on the market environment.
Appreciate it, Matt. If we look at where the market stands right now, there are a lot of contradictory signals coming through. Deal flow in private credit picked up somewhat over the quarter, even though the mix of quality across those deals was uneven. A consistent stream of strong opportunities is still coming our way, but at the same time more lower-quality deals are entering the market. With exit activity still muted versus what we've seen historically, sponsors are increasingly turning to dividend recapitalizations. Over in Europe, momentum decelerated compared with our 3rd quarter because of continued political and economic uncertainty, yet we're still finding some appealing deal flow there. Because there's so much liquidity in both the broadly syndicated loan market and private debt markets, sponsors have been prompted to pursue dual-track financings. A growing portion of $1 billion-plus LBOs are choosing the broadly syndicated market, and the illiquidity premium has been compressing; that said, following the Fed's rate cut in September, we've observed a bit more price discipline and we're cautiously optimistic that private credit spreads have hit their floor at SOFR plus 450. PIC and LUCIR covenants are still widely used by private debt managers as a way to secure mandates and allocations, but we stay extremely disciplined when it comes to our credit documentation and our willingness to accept PIC. PIC stood at 6.4% of total investment income at quarter end. Our preference is to apply PIC judiciously, in cases like funding a high ROE project or a carve-out acquisition where the PIC option is needed only for a set period, after which the project or acquisition produces enough cash flow to service the debt's full cash interest payment. Even with a mixed backdrop, we remain bullish on private credit over the long term. Issuers still place value on how quickly and reliably a sophisticated partner can execute a deal. From the investor side, we believe private debt will keep offering a premium spread versus other floating-rate asset classes, along with lower volatility. To go deeper on our portfolio and new investments, I'll hand things over to Raghav.
Thank you, Armen. Let me begin by reviewing our investment activity in the fourth quarter. Our pipeline got better over the quarter, but with competition running high and spreads tighter, as Armen noted, we're being very selective about new investments. Senior-secured loans to market-leading businesses with durable fundamentals, dependable cash flow, and solid downside protection remain our top priority. We're also working to diversify the portfolio, steer clear of industry concentration risk, and keep exposure to more cyclical sectors in check. Now for origination and repayment activity during the quarter: new-funded investment commitments, which include drawdowns from existing commitments, totaled $220 million, a 54% increase from the prior quarter. Prepayments from exits, other paydowns, and sales came to $177 million, and the weighted average spread on deployments for the quarter was roughly SOFR plus 570. First-lien loans made up 88% of our new originations. Among the notable investments this quarter was Walgreens Boots Alliance, an integrated healthcare, pharmacy, and retailer with a 170-year heritage. Sycamore Partners took the company private in a deal worth more than $20 billion, and afterward the sponsor carved the conglomerate into four separate operating businesses. Every one of those segments needed a tailored lending solution, so the sponsor looked for lenders able to act fast in underwriting the unique difficulties and turnaround potential of both the retail and pharmaceutical operations. Oaktree Strategies collaborated closely while evaluating a range of possible capital structures. In the end, Oaktree Funds served as joint lead arranger on the $2.5 billion first-in, last-out, first-lien term loan backing the U.S. retail business. Pricing on that loan came in at SOFR plus 700, together with 2.5 points of OIB, terms that are appealing given the industry risk and the complexity involved. Our extensive know-how in inventory appraisal, along with a long history of putting money into filos, gave us confidence in the collateral coverage behind the loan. This deal illustrates well how Oaktree stands ready to seize complicated but attractive investment chances. Switching to the portfolio: during the quarter, more than 40% of our portfolio companies saw markups averaging roughly 70 basis points on a weighted average basis, a sign of strengthening fundamentals across several holdings. At September 30th, first-lien senior-secured debt made up 83% of the portfolio, while debt investments carried a weighted average yield of 9.8%. Median EBITDA across our portfolio companies stood at about $150 million, which is $11 million lower than the previous quarter. Weighted average leverage at the portfolio companies ticked up to 5.2 times from 5.1 times, while weighted average interest coverage held steady at 2.2 times. As Matt noted, we've achieved concrete headway in lowering non-accruals and working through troubled investments, and that fed into a reduction in non-accruals for this quarter. Let me walk through those now, beginning with news on Mosaic Companies. We've been cooperating closely with Mosaic to capture value by separating its three business segments. Two of those segments found buyers, while the third is going through liquidation. You might remember that these steps produced a sizable cash paydown in the June quarter, and we collected further cash paydowns during the September quarter and after quarter end. From inception through today, the paydowns we've gotten add up to slightly more than 70% of what we originally invested, and paired with coupon payments, they've generated a positive IRR across the life of this loan; in our view, the proactive steps taken after Mosaic's tariff-related headwinds hit earlier this year helped us maximize recovery in a tough situation. We likewise made headway monetizing our investment in Oven Therapeutics, a loan secured by certain royalty rights plus public shares of ADC Therapeutics. After ADC's share price rose, we disposed of a portion of our ADC shares and directed the proceeds toward lowering the outstanding loan amount. Our remaining position in Oven Therapeutics continues to be marked at 99.5%, reflecting our view that we will continue monetizing the collateral supporting this loan and recover substantially all of the remaining loan balance. Although this issuer has appeared on our non-accrual list before, Baymar's first-lien loan has now been added to non-accrual status. The company's second-lien loan entered non-accrual during the third quarter; alongside other lenders and the company, we are collaborating closely to maximize value. At this point, I'll hand the call over to Chris so he can walk through our financial results.
Thanks, Raghav. During our 4th fiscal quarter, which ended September 30, 2025, adjusted net investment income came in at $35.4 million, or $0.40 per share, versus $32.5 million, or $0.37 per share, in the prior quarter. This quarter's improvement reflects fee income and interest expense returning to normalized levels after the one-time items that affected the 3rd quarter's results. NAV per share stood at $16.64, lower than $16.76 in the 3rd quarter, owing to unrealized depreciation on certain debt and equity investments. Adjusted total investment income rose to $76.9 million from $74.3 million in the 3rd quarter, mainly because of higher prepayment fees and dividend income. Net expenses fell modestly relative to the 3rd quarter. Interest expense came down thanks to the refinancing of our syndicated credit facility completed earlier this year, along with lower reference rates. Also, as you may remember, non-cash and non-recurring interest expense tied to the acceleration of deferred financing costs, primarily related to the termination of the Citibank SPV facility, affected our June quarter results. Our weighted average cost of borrowings was 6.5% at September 30, compared with 6.6% in the third quarter. In addition, roughly $1.9 million in incentive fees were waived because of our total return hurdle. Our leverage ratio ended the quarter at 0.97 times, a slight increase from 0.93 times last quarter, while total debt outstanding reached $1.5 billion. Our target leverage range of 0.9 times-1.25 times is still unchanged, and given our disciplined pace of capital deployment, we continue to sit at the low end of that range. Unsecured debt made up 64% of total debt at quarter end, a slight decline from the prior quarter; we have ample dry powder to fund investment commitments, with liquidity of approximately $695 million, including $80 million of cash and $615 million of undrawn capacity on our credit facility. Unfunded commitments, excluding those tied to the joint ventures, totaled $258.9 million, and about $246.9 million of that can be drawn immediately, since the remaining amount depends on portfolio companies hitting certain milestones before funds can be drawn. Now for our two joint ventures: combined, the JVs hold $513 million of investments, mainly in broadly syndicated loans across 73 portfolio companies. In the fourth fiscal quarter, the JVs produced ROEs of 12.4% in aggregate. Leverage at the JVs was 1.7 times, versus 1.3 times last quarter. We also received a $525,000 dividend from the Kemper JV. With that, I'll hand the call back to the operator to open it up for questions.
Morning, and thanks for fielding my questions. We certainly picked up on the shift in how much new net funding activity came through this quarter. December is usually a busy period for seasonal reasons, I realize that, but I wanted to ask whether you can already offer any preliminary read on what investment activity might look like in the December quarter this year, plus any unusually large repayments we ought to factor in.
Thanks, Melissa. Armen here. On the question of unusually large repayments, nothing of that sort is anticipated right now for the quarter that closes at the end of December. When it comes to deployment, I wouldn't say anything unusual is showing up in either direction — not heavier, not lighter — measured against December quarters we've been through before. Spreads have definitely come in somewhat, so we're careful in the way we put money to work, but I don't anticipate any meaningful departure from prior quarters when it comes to deployment or leverage levels this quarter.
All right, I appreciate that. Another item tied to what you said about spreads coming in — I saw that the yield on new investments this quarter moved up a notch, roughly 60 basis points above what we saw last quarter. My assumption is that this ties to how complex the Walgreens deal was, both its complexity and its size. So, first, is that correct? And second, how do you see the pipeline for deals of that kind, where there could be greater complexity and pricing involved? Thanks so much.
Hi, Melissa. This is Chris, and thanks for asking. I'll take the first part, and maybe Armen can chime in a bit regarding the pipeline. Yes, on the change from quarter to quarter — you're correct to point at Walgreens. Something else worth mentioning regarding the June quarter is that, on balance, a somewhat larger share of our originations went into loans indexed to IBOR. That means when you look at absolute coupons, June came in a bit lower because of it; we do hedge the whole exposure back into U.S. dollars. Once that hedging effect is factored in, there's a modest lift, though it does introduce a bit of noise from one quarter to the next. Armen, anything you'd like to add?
Yes. Non-sponsored direct lending is an area where we maintain a highly active origination effort. Walgreens, I'd say, is notable for being a loan with a fairly elevated spread. Looking at what we'd expect to originate during the December quarter, nothing strikes me as reaching a spread that high; a handful of opportunities we're currently pursuing could land somewhat above the 450 to 500 spread typical for sponsor lending, though offering forward guidance now feels premature. My view is simply that the Walgreens transaction cannot be replicated, I don't believe, during the fourth quarter. Apologies — I mean the fourth calendar quarter.
Yep. Understood. Thanks.
Hey, guys. Good morning. Regarding the non-accrual still on the books, there still appears to be a heavy skew towards healthcare and pharma. Could you share a bit more color about what's happening in those particular segments?
Sure; this is Armen. Within the life sciences space, we hold, or held, a few sizable positions. The count isn't large, but unfortunately these were some bigger positions that remain subject to workouts, with SIO2 being, I'd say, the most material among them — a name we've discussed on prior calls. That's essentially the situation. We keep working through cases that, by now, have spent several years in the portfolio. All of them are roughly stable, perhaps marginally better, yet still not where we could either exit or shift them into accrual status, unfortunately. We haven't brought in additional life sciences or healthcare names that have run into trouble during recent quarters. Again, a small handful of positions established a few years back keep dragging on the non-accrual bucket.
Got it. As a quick follow-up, is there any workout strategies going on with those long-standing non-accruals?
These are operational workouts more than anything. From a capital structure standpoint, they've already been restructured, but operational gains are being achieved. We collaborate closely with management teams to push that performance. Where feasible, we partner with management to divest assets and either cover cash burn or return capital or make distributions to our position. Nothing major or monumental, I'd say, is likely to occur near term regarding those positions. It's essentially blocking and tackling alongside an operational turnaround.
Appreciate the color. Thank you.
Great. Thank you, operator. Thank you to everybody for joining. Please reach out with any questions. We're happy to jump on the phone. Have a great day.
That brings an end to the conference call for today. Thanks to everyone for taking part. You're free to disconnect at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Oaktree Specialty Lending Corporation transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Oaktree Specialty Lending Corporation earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.